Mitotane (2,4′-DDD), Antineoplastic Agent

Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions. - Mechanism of Action & Protocol.

Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro

Mitotane, CAS#:53-19-0

Mitotane Tablets Exporter,Wholesale Mitotane Tablets Supplier from Delhi India

Mitotane, CAS#:53-19-0

Frontiers Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

Separations, Free Full-Text

Mitotan 53-19-0 wiki

Adrenocortical carcinoma: a clinician's update

Mitotane cancer drug molecule. Skeletal formula Stock Vector Image & Art - Alamy

Frontiers Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study

Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines in: Endocrine-Related Cancer Volume 15 Issue 2 (2008)

Frontiers Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study